News & Media

Aug 01 / 2024

Hemostemix Closes its Funded Manufacturing Services Agreement with CytoImmune, Restarting Production of ACP-01 
Jun 11 / 2024

Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
Jun 03 / 2024

Hemostemix Announces Strategic Manufacturing Partnership with CytoImmune Therapeutics and $1,800,000 in Financing Commitments
Mar 07 / 2024

Hemostemix Announces Engagement of Oak Hill Asset Management Inc.
Feb 06 / 2024

Hemostemix Announces Updated Phase II Randomized Clinical Trial Results Published by the Journal of Biomedical Research and Environmental Sciences
Dec 29 / 2023

Hemostemix Clarifies its October 3, 2023 News Release
Oct 30 / 2023

Hemostemix’s 4th Heart Study Published in Stem Cell Research & Therapy Confirms Breakthrough Treatment for Heart Disease
Oct 23 / 2023

Hemostemix Announces Amendment of its $2.5 Million 5 Year Convertible Debenture Issued on June 11, 2021, Resulting in an Expected Interest Saving of Approximately $570,000
Oct 03 / 2023

Hemostemix Closed $320,125 Private Placement
Sep 28 / 2023

Hemostemix Announces Private Placement
Sep 12 / 2023

Hemostemix Announces New Publication: How NCP-01 Supports Brain Computer Interfaces
Aug 29 / 2023

Hemostemix Announces the Incorporation of Hemostemix Quebec Inc. and $6 Million in Grant Applications
Aug 14 / 2023

Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement
Aug 08 / 2023

Hemostemix Submits its Retrospective Heart Study to Leading Stem Cell Journal and has Prepared its CLI Phase II Clinical Trial  Manuscript for Peer Review
Jul 05 / 2023

The Benefits of ACP-01 Stem Cell Therapy: Can it Save Limbs and thereby Lives?
Jun 28 / 2023

Hemostemix Closes $403,539 of the Unit Private Placement
Jun 21 / 2023

Hemostemix’s Private Placement Use of Proceeds
Jun 01 / 2023

Hemostemix Announces Unit Private Placement
May 02 / 2023

Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
Apr 03 / 2023

Hemostemix’ Second Round Interviews with Executive Vice President Business Development Candidates
Mar 29 / 2023

Hemostemix Engages Montreal’s RobboDesign to SEO its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally
Mar 21 / 2023

HEMOSTEMIX CLOSES $762,400 OF THE UNIT PRIVATE PLACEMENT
Mar 08 / 2023

Hemostemix Unit Offering Repriced
Mar 07 / 2023

Hemostemix Offers up to 500 6% Convertible Debentures,Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval
Feb 01 / 2023

Hemostemix Announces Unit Private Placement
Jan 31 / 2023

The Force Family Office Engaged by Hemostemix
Jan 30 / 2023

Hemostemix’ “Your Fountain of Youth” Trademark Granted by Switzerland
Jan 26 / 2023

Hemostemix’ “Your Fountain of Youth” Trademark Granted by Japan Patent Office
Jan 25 / 2023

Hemostemix Wins Arbitration Decision
Jan 23 / 2023

Hemostemix Hiring 4 New Biotechnologists in Montreal and Applying for Grants to Fund up to 75% of 5-Year Costs
Jan 19 / 2023

Hemostemix Announces Letter of Commitment, Non-dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation
Dec 08 / 2022

Hemostemix Issued “Your Fountain of Youth” Trademark by Cyprus
Nov 30 / 2022

Hemostemix Thanks Niem Malo, Beefstro’s Founder, for his ACP-01 Testimonial Interview
Nov 15 / 2022

Hemostemix Announces Advancements in its Automation of Production
Oct 26 / 2022

Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials
Oct 25 / 2022

Hemostemix Announces Presentation to the Emerging Growth Conference
Oct 19 / 2022

Hemostemix Announces NCP-01 Study to Address a $10 Billion Pain Market
Oct 04 / 2022

Hemostemix Announces Exploring Clinical Trial Financing Alternatives
Sep 27 / 2022

Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its Scientific Advisory Board
Sep 20 / 2022

Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board
Sep 16 / 2022

Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Sep 15 / 2022

Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Sep 14 / 2022

Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to its Scientific Advisory Board
Sep 14 / 2022

Hemostemix Announces its Presentation to the Emerging Growth Conference
Sep 12 / 2022

Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
Aug 31 / 2022

Hemostemix Announces A Clarification
Aug 30 / 2022

Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections
Aug 22 / 2022

Hemostemix Announces Closing of UNIT Private Placement
Aug 19 / 2022

Hemostemix Announces Unit Private Placement
Aug 12 / 2022

Hemostemix Announces Closing of Second Tranche of UNIT Private Placement